鼻腔内注射的埃斯基坦胺可显著缓解电治疗 (ECT) 无反应患者的抑郁症严重程度和自杀念头
Erhan Kavakbasi1,2, Kevin Rosemann3, Mert Yilmaz3
1Department of Psychiatry, University Hospital Münster, University of Münster, Albert-Schweitzer-Campus 1, Building A9, 48149, Münster, Germany. erhan.kavakbasi@uni-muenster.de.
概括
鼻内乙胺 (ESK) 是有效的治疗耐药性抑郁症 (TRD),即使在那些没有响应电疗法 (ECT) 的患者. 这项研究发现,以前的ECT不响应对ESK治疗结果没有显著的影响.
科学领域:
- 精神病学是一个精神病学.
- 药理学 药理学是指药理学的学科.
- 临床神经科学 临床神经科学
背景情况:
- 鼻内乙胺 (ESK) 为治疗耐药性抑郁症 (TRD) 提供了一种新的治疗选择.
- 患有电疗法 (ECT) 无反应病史的患者经常被排除在ESK研究之外,这使得了解其在这个人群中的有效性存在差距.
- 关于在ECT非响应者中ESK有效性的数据有限.
研究的目的:
- 调查TRD患者内鼻ESK的现实有效性,与没有 (ECT-) 患者相比,TRD患者有ECT非响应史 (ECT+).
- 确定ECT不响应对治疗结果的影响,包括响应和缓解率以及症状严重程度.
主要方法:
- 一项对96名TRD住院患者的回顾性研究,将39名ECT+患者与57名ECT-患者进行比较.
- 使用因子差异分析 (ANOVA) 来评估ECT不响应对治疗结果的影响.
- 评估了蒙哥马利-阿斯伯格抑郁评分表 (MADRS) 和贝克抑郁库存-II (BDI-II) 评分的变化,以及反应和缓解率.
主要成果:
- 在MADRS得分 (p=0.002) 上观察到ECT无反应的显著主要影响 (p=0.002).
- 与ECT组相比,ECT+组的响应率 (34.9%与21.9%) 和缓解率 (24.4%与12.1%) 并没有显著降低.
- 在ECT+组中,MADRS和BDI-II分数的显著改善被注意到,没有重大安全问题.
结论:
- 历史的ECT不响应并没有显著影响TRD的鼻内ESK治疗的整体结果.
- 这些发现支持向没有对ECT反应的TRD患者提供ESK,因为现有的替代治疗方法有限.
- 内鼻式ESK显示出作为耐药抑郁症的可行治疗选择的潜力,即使在以前ECT失败的患者中也是如此.
相关概念视频
Electroconvulsive Therapy
203
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
203
Antidepressant Drugs: MAOIs and Other Agents
377
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
377
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
617
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
617
Antidepressant Drugs: Overview
792
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
792
Antiepileptic Drugs: Potassium Channel Activators
286
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
286
Psychosis: Goals of Pharmacotherapy
214
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
214


